Abbvie Inc. vs Teva Pharmaceutical Industries Limited
ABBV vs TEVA — side-by-side comparison from reported financials. ABBV leads 7, TEVA leads 4 of 11 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Teva Pharmaceutical Industries Limited
TEVA · Healthcare
$41.21+4.99%Strained
| Metric | ABBV | TEVA |
|---|---|---|
| Price | $276.43 | $41.21 |
| Market cap | $488B | $48.1B |
| Revenue (TTM) | $64.4B | $17.3B |
| Revenue growth | +1.8% | +5.0% |
| Net margin | 9.8% | 4.1% |
| Free cash flow | $18.2B | $1.35B |
| Net cash (debt) | ($56.2B) | $1.74B |
| 1-year price return | +19.8% | +105.6% |
| P/E | 77.4 | 63.2 |
| P/E vs own history (cheap-side %) | 23% | 0% |
| Dividend yield | 2.45% | — |
| Return on equity | 96% | 9% |
| Altman Z-score | 2.33 | 0.63 |
| CV checks passed | 9 of 11 | 7 of 11 |
| Employees | 57,000 | 32,842 |
Full résumé-style profiles: ABBV CV · TEVA CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.